NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University Hospital, Essen
Asan Medical Center
Fudan University
The First Affiliated Hospital of Zhengzhou University
Fujian Cancer Hospital
Case Comprehensive Cancer Center
Jiangsu Cancer Institute & Hospital
Kidney Cancer Research Bureau
BeBetter Med Inc
Uppsala University
Istituto Oncologico Veneto IRCCS
Ruijin Hospital
National Cheng-Kung University Hospital
Ludwig-Maximilians - University of Munich
Hospital Israelita Albert Einstein
Second Affiliated Hospital, School of Medicine, Zhejiang University
GERCOR - Multidisciplinary Oncology Cooperative Group
Jinling Hospital, China
Fujian Medical University Union Hospital
Changhai Hospital
Sun Yat-sen University
Federation Francophone de Cancerologie Digestive
Shandong Cancer Hospital and Institute
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Criterium, Inc.
Sichuan University
Nanfang Hospital, Southern Medical University
Qilu Pharmaceutical Co., Ltd.
Salah Azaïz Cancer Institute
Sun Yat-sen University
University of Roma La Sapienza
Yixing People's Hospital
Xijing Hospital
Xijing Hospital
National Cancer Institute, Naples
Zhujiang Hospital
Zhujiang Hospital
Sixth Affiliated Hospital, Sun Yat-sen University
Zhejiang University
Fudan University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Henan Cancer Hospital
The First Affiliated Hospital with Nanjing Medical University
Tanta University
Fudan University
Third Affiliated Hospital, Sun Yat-Sen University
Ludwig-Maximilians - University of Munich
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University